Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.

Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol. 2012 Jan-Feb; 11(1):15-31.

View in: PubMed

subject areas

Adolescent
Adult
Aged
Dose-Response Relationship, Drug
Double-Blind Method
Drug Therapy, Combination
Endpoint Determination
Female
Genotype
Hepacivirus
Hepatitis C, Chronic
Humans
Interferon-alpha
International Cooperation
Male
Middle Aged
Nucleosides
Polyethylene Glycols
Recombinant Proteins
Ribavirin
RNA, Viral
Treatment Outcome
Young Adult

authors with profiles

Donald M. Jensen